Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy

SIMPLE SUMMARY: Anti-EGFR-related skin toxicity has been described as a predictive biomarker of response in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC). With the CAVE mCRC trial we previously provided the first evidence of the activity of cetuximab plus avelumab as rechallen...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardiello, Davide, Famiglietti, Vincenzo, Napolitano, Stefania, Esposito, Lucia, Normanno, Nicola, Avallone, Antonio, Latiano, Tiziana, Maiello, Evaristo, Pietrantonio, Filippo, Cremolini, Chiara, Santabarbara, Giuseppe, Pinto, Carmine, Troiani, Teresa, Martinelli, Erika, Ciardiello, Fortunato, Martini, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616320/
https://www.ncbi.nlm.nih.gov/pubmed/34830870
http://dx.doi.org/10.3390/cancers13225715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616320/
https://www.ncbi.nlm.nih.gov/pubmed/34830870
http://dx.doi.org/10.3390/cancers13225715

Ejemplares similares